重组人源化抗VEGF单克隆抗体注射液对照安维汀在健康人中单次给药人体药代动力学、安全性及免疫原性比对研究
[Translation] Comparative study on the pharmacokinetics, safety and immunogenicity of recombinant humanized anti-VEGF monoclonal antibody injection versus Avastin in healthy subjects after single administration
主要目的:评价重组人源化抗VEGF单克隆抗体注射液与贝伐珠单抗注射液(安维汀®)在健康男性受试者中单次给药的药代动力学参数的相似性。 次要目的:评价重组人源化抗VEGF单克隆抗体注射液与贝伐珠单抗注射液(安维汀®)在健康男性受试者中单次给药的安全性、耐受性和免疫原性。
[Translation] Primary objective: To evaluate the similarity of pharmacokinetic parameters of recombinant humanized anti-VEGF monoclonal antibody injection and bevacizumab injection (Avastin®) in healthy male subjects after single administration. Secondary objective: To evaluate the safety, tolerability and immunogenicity of recombinant humanized anti-VEGF monoclonal antibody injection and bevacizumab injection (Avastin®) in healthy male subjects after single administration.
/ Not yet recruitingPhase 1/2 一项评价KD6001注射液联合替雷利珠单抗±贝伐珠单抗在晚期肝癌患者及其他实体瘤患者中的安全性、耐受性、药代动力学和初步疗效的临床研究
[Translation] A clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of KD6001 injection combined with tislelizumab ± bevacizumab in patients with advanced liver cancer and other solid tumors
评价KD6001注射液联合替雷利珠单抗±贝伐珠单抗在晚期肝癌患者及其他实体瘤患者中的安全性、耐受性、药代动力学和初步疗效
[Translation] To evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of KD6001 injection combined with tislelizumab ± bevacizumab in patients with advanced liver cancer and other solid tumors
100 Clinical Results associated with Shanghai Kangdai Biomedical Technology Co., Ltd.
0 Patents (Medical) associated with Shanghai Kangdai Biomedical Technology Co., Ltd.
100 Deals associated with Shanghai Kangdai Biomedical Technology Co., Ltd.
100 Translational Medicine associated with Shanghai Kangdai Biomedical Technology Co., Ltd.